Pfizer Inc — 13F Holdings & Portfolio

CIK 78003 · latest 13F-HR filed 2026-08-13

Pfizer Inc manages $170.4M in 13F-reported U.S. long-equity assets across 20 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ALLO (27.55%), CELC (17.35%), ARVN (16.24%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 0 new positions and exited 1; 5 existing positions rose in reported value and 10 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$170.4M

Long-equity book

Holdings
20

Distinct positions

Period
2026-06-30

Filed 2026-08-13

Q/Q Activity
+0 / −1 / ↑5 / ↓10

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 95.8%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People
Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

Show all 5 →

Top Trims

Show all 10 →

New Positions

  • No new positions this quarter.
Show all 0 →

Exited Positions

Show all 1 →

Pfizer Inc Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 ALLOGENE THERAPEUTICS INC ALLO 019770106 $46.9M 27.55% 22,032,040 SH
2 CELCUITY INC CELC 15102K100 $29.6M 17.35% 295,652 SH
3 ARVINAS INC ARVN 04335A105 $27.7M 16.24% 3,457,815 SH
4 PYXIS ONCOLOGY INC PYXS 747324101 $16.5M 9.68% 5,952,263 SH
5 WAVE LIFE SCIENCES LTD WVE Y95308105 $10.9M 6.42% 1,875,000 SH
6 BIOHAVEN LTD BHVN G1110E107 $8.0M 4.70% 505,645 SH
7 CARIBOU BIOSCIENCES INC CRBU 142038108 $7.9M 4.63% 4,690,431 SH
8 SPERO THERAPEUTICS INC SPRO 84833T103 $5.3M 3.13% 2,362,348 SH
9 ZENTALIS PHARMACEUTICALS INC ZNTL 98943L107 $3.9M 2.26% 953,834 SH
10 ORIC PHARMACEUTICALS INC ORIC 68622P109 $3.6M 2.09% 372,904 SH
11 CARDIFF ONCOLOGY INC CRDF 14147L108 $3.0M 1.77% 2,411,575 SH
12 PYXIS ONCOLOGY INC PYXS 747324101 $3.0M 1.76% 1,080,507 SH
13 ZURA BIO LTD ZURA G9TY5A101 $2.9M 1.69% 538,841 SH
14 AGOMAB THERAPEUTICS NV AGMB 00860C102 $1.0M 0.61% 75,000 SH
15 BOLT BIOTHERAPEUTICS INC BOLT 097702203 $133.8K 0.08% 31,305 SH
16 NEXTCURE INC NXTC 65343E207 $61.4K 0.04% 37,346 SH
17 GINKGO BIOWORKS HOLDINGS INC DNA 37611X209 $27.5K 0.02% 2,681 SH
18 SENSEONICS HLDGS INC SENS 81727U105 $12.4K 0.01% 2,171 SH
19 NEXTCURE INC NXTC 65343E207 $11.5K 0.01% 7,001 SH
20 GINKGO BIOWORKS HOLDINGS INC DNA 37611X209 $2.5K 0.00% 247 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-13 $170.4M 20 0000078003-26-000102
2026-03-31 2026-05-12 $238.8M 21 0000078003-26-000064
2025-12-31 2026-02-12 $236.5M 21 0000078003-26-000013
2025-09-30 2025-11-13 $437.5M 24 0000078003-25-000161
Filer Information
Address
66 HUDSON BOULEVARD EAST
NEW YORK, NY 10001-2192
Phone
(212) 733-2323
Filing Manager
Pfizer Inc
New York, NY
Signatory
Madelyn D. Purcell
Assistant General Counsel